1. Home
  2. JFIN vs ENLV Comparison

JFIN vs ENLV Comparison

Compare JFIN & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JFIN

Jiayin Group Inc.

HOLD

Current Price

$4.05

Market Cap

201.5M

Sector

Finance

ML Signal

HOLD

Logo Enlivex Therapeutics Ltd.

ENLV

Enlivex Therapeutics Ltd.

HOLD

Current Price

$0.67

Market Cap

196.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFIN
ENLV
Founded
2011
2005
Country
China
Israel
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
201.5M
196.2M
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
JFIN
ENLV
Price
$4.05
$0.67
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$20.00
AVG Volume (30 Days)
75.3K
409.3K
Earning Date
06-03-2026
05-29-2026
Dividend Yield
17.47%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.70
$0.66
52 Week High
$18.70
$2.10

Technical Indicators

Market Signals
Indicator
JFIN
ENLV
Relative Strength Index (RSI) 42.97 39.07
Support Level $3.80 $0.66
Resistance Level $4.54 $1.23
Average True Range (ATR) 0.23 0.07
MACD -0.00 -0.01
Stochastic Oscillator 36.98 6.44

Price Performance

Historical Comparison
JFIN
ENLV

About JFIN Jiayin Group Inc.

Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.

About ENLV Enlivex Therapeutics Ltd.

Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.

Share on Social Networks: